GKOS

Glaukos Corp

FDA PDUFA Target Action Date

Thursday, January 1, 2026

145 days ago

approved

Drug Information

Drug Name: iDose TR (Travoprost Intraocular Implant) (CT.gov)
Application Type: NDA
Indication: Open-angle glaucoma
Approved As: iDose TR (travoprost intraocular implant)

Filing Details

Company: Glaukos Corp →
Stock Ticker: GKOS
SEC CIK: 0001192448
Source: ClinicalTrials.gov →

What is a PDUFA Date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.

Standard Review: 10 months from filing acceptance
Priority Review: 6 months from filing acceptance
Possible Outcomes: Approval, Complete Response Letter (CRL), or extension

Explore Glaukos Corp

View Glaukos Corp's full pipeline, approved drugs, and clinical trials.

View Pipeline → FDA Calendar →

Data sourced from SEC EDGAR filings. Last updated: 2026-03-22. Report an issue